Documentation

• EQA Technical Documents

  • 2026_FR.44 EQA Programs Work Schedule Rev.00
  • PRT.01 SEROCON EQA PROGRAMS PROTOCOL Rev.04
  • PR.13 PROCEDURE FOR THE EVALUATION OF COMPLAINTS AND OBJECTIONS Rev.02
  • FR.28 Complaint and Objection Request Form Rev.01

• Prospectuses

  • PRP.32 Glucometer EQC (IFU). Rev.00
  • PRP.31 Immunoassay-ACTH EQC (IFU). Rev.02
  • PRP.30 POCT-Cardiac Marker EQC (IFU). Rev.02
  • PRP.29 Urine Toxicology EQC (IFU). Rev.02
  • PRP.27 Viral Marker EQC (IFU). Rev.02
  • PRP.26 Torch Panel EQC (IFU). Rev.02
  • PRP.25 Urinalysis EQC (IFU). Rev.02
  • PRP.24 Sedimantation EQC (IFU). Rev.02
  • PRP.23 Blood Gases EQC (IFU). Rev.02
  • PRP.22 IMMUNOHEMATOLOGY EQC (IFU). Rev.02
  • PRP.21 Urine Chemistry EQC (IFU). Rev.02
  • PRP.20 Hematology EQC (IFU). Rev.02
  • PRP.19 Ethanol-Amonia EQC (IFU). Rev.02
  • PRP.15 Cardiac Marker EQC (IFU). Rev.02
  • PRP.18 Cardiac Marker-S EQC (IFU). Rev.02
  • PRP.14 Procalcitonin EQC (IFU).Rev.02
  • PRP.12 TDM EQC (IFU). Rev.02
  • PRP.11 Immunosuppressive Drug EQC (IFU) .Rev.02
  • PRP.10 THALASSEMIA EQC (IFU).Rev.02
  • PRP.09 Prenatal Screening EQC (IFU). Rev.02